Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Accumulated Depreciation & Amortization: 2021-2022

Historic Accumulated Depreciation & Amortization for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to $16,187.

  • Cardiol Therapeutics' Accumulated Depreciation & Amortization fell 3.48% to $16,187 in Q3 2022 from the same period last year, while for Sep 2022 it was $70,604, marking a year-over-year change of. This contributed to the annual value of $153,645 for FY2024, which is 145.49% up from last year.
  • Latest data reveals that Cardiol Therapeutics reported Accumulated Depreciation & Amortization of $16,187 as of Q3 2022, which was down 2.24% from $16,558 recorded in Q2 2022.
  • Over the past 5 years, Cardiol Therapeutics' Accumulated Depreciation & Amortization peaked at $21,111 during Q2 2021, and registered a low of $16,187 during Q3 2022.
  • Over the past 2 years, Cardiol Therapeutics' median Accumulated Depreciation & Amortization value was $16,748 (recorded in 2021), while the average stood at $17,881.
  • The largest annual percentage gain for Cardiol Therapeutics' Accumulated Depreciation & Amortization in the last 5 years was 26.57% (2022), contrasted with its biggest fall of 21.57% (2022).
  • Cardiol Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $16,748 in 2021, then declined by 3.48% to $16,187 in 2022.
  • Its Accumulated Depreciation & Amortization stands at $16,187 for Q3 2022, versus $16,558 for Q2 2022 and $21,111 for Q1 2022.